$1.45
2.03% day before yesterday
Nasdaq, May 23, 10:00 pm CET
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Geron Corporation Stock price

$1.45
+0.06 4.32% 1M
-2.65 64.63% 6M
-2.09 59.04% YTD
-2.04 58.45% 1Y
+0.18 14.17% 3Y
-0.39 21.20% 5Y
-2.50 63.29% 10Y
Nasdaq, Closing price Fri, May 23 2025
-0.03 2.03%
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Key metrics

Market capitalization $923.53m
Enterprise Value $645.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.55
P/S ratio (TTM) P/S ratio 7.94
P/B ratio (TTM) P/B ratio 3.44
Revenue growth (TTM) Revenue growth 22,263.46%
Revenue (TTM) Revenue $116.29m
EBIT (operating result TTM) EBIT $-136.01m
Free Cash Flow (TTM) Free Cash Flow $-204.34m
Cash position $396.88m
EPS (TTM) EPS $-0.21
P/E forward negative
P/S forward 4.65
EV/Sales forward 3.25
Short interest 10.48%
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

Buy
67%
Hold
33%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
116 116
22,263% 22,263%
100%
- Direct Costs 2.46 2.46
-
2%
114 114
-
98%
- Selling and Administrative Expenses 159 159
90% 90%
136%
- Research and Development Expense 89 89
30% 30%
77%
-135 -135
36% 36%
-116%
- Depreciation and Amortization 1.42 1.42
216% 216%
1%
EBIT (Operating Income) EBIT -136 -136
35% 35%
-117%
Net Profit -139 -139
31% 31%
-120%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
Business Wire
6 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares o...
Neutral
GlobeNewsWire
9 days ago
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigat...
Neutral
GlobeNewsWire
13 days ago
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today